N-acetylcysteine-amide - Nacuity Pharmaceuticals

Drug Profile

N-acetylcysteine-amide - Nacuity Pharmaceuticals

Alternative Names: N-acetylcysteine-amide; NACA - Nacuity Pharmaceuticals; NPI 001

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nacuity Pharmaceuticals
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Retinitis pigmentosa

Most Recent Events

  • 06 Aug 2017 Phase-I clinical trials in Retinitis pigmentosa (In volunteers) in Australia (PO) (ACTRN12617000911392p)
  • 16 Jun 2017 Nacuity Pharmaceuticals plans a phase I trial for Retinitis pigmentosa (In volunteers) in Australia (ACTRN12617000911392p)
  • 18 Jan 2017 Foundation Fighting Blindness supports the clinical development of N-acetylcysteine-amide for Retinitis pigmentosa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top